Healios K.K. (OTCMKTS:HLOSF) Short Interest Update

Healios K.K. (OTCMKTS:HLOSF) was the recipient of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 500 shares, a drop of 89.6% from the November 15th total of 4,800 shares. Based on an average daily volume of 500 shares, the short-interest ratio is presently 1.0 days.

Healios K.K. Stock Performance

HLOSF stock remained flat at 1.35 during trading on Thursday. The business has a 50 day simple moving average of 1.46 and a 200 day simple moving average of 1.36. Healios K.K. has a 1-year low of 0.93 and a 1-year high of 1.73.

About Healios K.K.

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease.